Abstract：Objective To investigate the effect of oridonin on the human acute lymphocytic leukemia cell line Jurkat and its mechanism. Methods Jurkat cells were cultured in vitro and treated with various concentrations (0, 1.25, 2.5, 5, and 10 μmol/L) of oridonin for different lengths of time (24, 48, and 72 hours). The proliferation of Jurkat cells was analyzed by MTT assay. The changes in nuclear morphology were evaluated by fluorescence microscopy at 12 hours after treatment with various concentrations of oridonin. The expression levels of Brg1, P53, and C-myc were determined by semi-quantitative Western blot in Jurkat cells treated with various concentrations of oridonin for 24 hours or 5 μmol/L oridonin for various lengths of time (0, 2, 6, 12, and 24 hours). The expression levels of P53 and C-myc and proliferation of Jurkat cells were evaluated after Brg1 expression was knocked down by Brg1-specific siRNA. Results Compared with the control group, the proliferation of oridonin-treated Jurkat cells was significantly inhibited in a concentration-and time-dependent manner (P < 0.05). According to the florescence microscopic analysis, oridonin treatment led to nuclear pyknosis in Jurkat cells. Compared with the control group, Jurkat cells treated with 5 μmol/L oridonin had reduced expression of Brg1 and C-myc but elevated expression of P53. Brg1 knock-down led to a significant reduction in proliferation of Jurkat cells (P < 0.05), up-regulated expression of P53, and down-regulated expression of C-myc. Conclusions Oridonin can inhibit the proliferation of Jurkat cells, probably via the Brg1 signaling pathway.
YE Zhen-Zhen,XUE Fei-Long,DING Wen-Ping et al. Oridonin inhibits proliferation of Jurkat cells via the down-regulation of Brg1[J]. CJCP, 2017, 19(11): 1208-1212.
Zhao Z, Chen Y. Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies[J]. Curr Pharm Biotechnol, 2014, 15(11):1083-1092.
[4]
Ding Y, Ding C, Ye N, et al. Discovery and development of natural product oridonin-inspired anticancer agents[J]. Eur J Med Chem, 2016, 122:102-117.
Guo Y, Shan Q, Gong Y, et al. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway[J]. Cancer Biol Ther, 2012, 13(13):1244-1254.
[7]
Shi J, Whyte WA, Zepeda-Mendoza CJ, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation[J]. Genes Dev, 2013, 27(24):2648-2662.
Tian W, Chen SY. Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin[J]. Chin J Integr Med, 2013, 19(4):315-320.
[11]
Yao Z, Xie F, Li M, et al. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells[J]. Cell Death Dis, 2017, 8(2):e2633.
[12]
Xu S, Yao H, Luo S, et al. A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway[J]. J Med Chem, 2017, 60(4):1449-1468.
Wu Q, Lian JB, Stein JL, et al. The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer[J]. Epigenomics, 2017, 9(6):919-931.
[15]
Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery:impact of SWI/SNF perturbations in cancer[J]. Cancer Res, 2009, 69(21):8223-8230.
[16]
Lu P, Roberts CW. The SWI/SNF tumor suppressor complex:Regulation of promoter nucleosomes and beyond[J]. Nucleus, 2013, 4(5):374-378.
[17]
Bai J, Mei PJ, Liu H, et al. BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro[J]. J Cancer Res Clin Oncol, 2012, 138(6):991-998.
[18]
Bai J, Mei P, Zhang C, et al. BRG1 is a prognostic marker and potential therapeutic target in human breast cancer[J]. PLoS One, 2013, 8(3):e59772.
[19]
Naidu SR, Love IM, Imbalzano AN, et al. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells[J]. Oncogene, 2009, 28(27):2492-2501.
